PLAT and androgen insensitivity syndrome: Only 3% to 9% of AIS patients receive intravenous recombinant tissue plasminogen activator, and most AIS patients often miss the opportunity to receive recombinant tissue plasminogen activator intravenous thrombolytic therapy.[34–36] patients with AIS of proximal large vessel occlusion who have been evaluated by rigorous imaging for more than 6 hours can be treated by EVT.